FDA Grants RMAT Designation for SENTI-202, Senti Bio Reports Positive Phase 1 AML Data
Summary
Senti Biosciences announced significant positive developments for its lead program, SENTI-202, including updated positive preliminary Phase 1 clinical data in relapsed/refractory acute myeloid leukemia (AML) and the receipt of Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The RMAT designation is a critical regulatory milestone, indicating the FDA's recognition of SENTI-202's potential to address an unmet medical need and offering expedited development and review. This news, coupled with encouraging clinical data demonstrating favorable response rates and safety, provides strong validation for Senti Bio's Gene Circuit platform and its lead candidate. While the company also reported Q4 and full-year 2025 financial results, including a net loss of $14.5 million for Q4 and $61.4 million for the full year, and a cash position of $16.4 million, the clinical and regulatory advancements are the primary drivers for the stock. Investors will now closely monitor the accelerated development pathway for SENTI-202 and future clinical milestones.
At the time of this announcement, SNTI was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $0.80 to $5.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.